Neupro

Neupro

rotigotine

Manufacturer:

UCB

Distributor:

Zuellig
/
Agencia Lei Va Hong
Concise Prescribing Info
Contents
Rotigotine
Indications/Uses
Treatment of signs & symptoms of early-stage idiopathic Parkinson's disease, as monotherapy or in combination w/ levodopa ie, over the course of the disease, through end of dose or 'on-off' fluctuations.
Dosage/Direction for Use
Apply on skin once daily. Rotate application site daily. Do not apply to the same site more than once every 14 days. Change patch at around the same time daily. Monotherapy (early stage of Parkinson's disease) Initially 1 patch of 2 mg/24 hr daily. From 2nd wk, increase dose by 2 mg, on a wkly basis, until maintenance dose is reached. Usual maintenance dose: 6-8 mg/day (reached w/in 3-4 wk). Max: 8 mg/day. Combination w/ levodopa (advanced stage of Parkinson's disease) Initially 1 patch of 4 mg/24 hr daily. From 2nd wk, increase dose by 2 mg, on a wkly basis until maintenance dose is reached. Usual maintenance dose: 8-16 mg/day (reached w/in 3-7 wk). Max: 16 mg/day. Discontinue gradually.
Contraindications
Hypersensitivity. Remove patch prior to MRI or cardioversion.
Special Precautions
Monitor BP regularly. Eye examinations are recommended at regular intervals. Serious liver problems. Loss of consciousness; drowsiness, sudden somnolence. Impulse control disorders; abnormal thinking & behaviour. Skin reactions. Avoid sun & solarium exposure. Taper treatment to avoid dopamine agonist w/drawal syndrome (DAWS). Contains Na metabisulphite (E223). May impair ability to drive & use machines. Pregnancy & lactation. Childn.
Adverse Reactions
Sleepiness, dizziness, headache; nausea, vomiting; skin irritations under the patch eg, redness, itching. Hallucinations; difficulty falling asleep, sleep disorder, difficulty sleeping, nightmare, unusual dreams; loss of consciousness, dyskinesia, feeling dizzy when standing up; vertigo; palpitation, low BP when standing up, HTN; hiccups; constipation, dry mouth, heartburn; redness, increased sweating, itching; swelling of legs & feet; feeling weak & tired; falling; wt loss; impulse control disorders.
Drug Interactions
Decreased effect w/ antipsychotics or metoclopramide. Caution w/ antihypertensives or other medicines that may lower BP, sedatives or other CNS depressants (eg, benzodiazepines).
MIMS Class
Antiparkinsonian Drugs
ATC Classification
N04BC09 - rotigotine ; Belongs to the class of dopamine agonists. Used in the management of Parkinson's disease.
Presentation/Packing
Form
Neupro transdermal patch 2 mg/24 hr
Packing/Price
10 cm<sup>2</sup> x 28 × 1's
Form
Neupro transdermal patch 4 mg/24 hr
Packing/Price
20 cm<sup>2</sup> x 28 × 1's
Form
Neupro transdermal patch 6 mg/24 hr
Packing/Price
30 cm<sup>2</sup> x 28 × 1's
Form
Neupro transdermal patch 8 mg/24 hr
Packing/Price
40 cm<sup>2</sup> x 28 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in